Alnylam Pharmaceuticals has reportedly been making strides within the healthcare sector, making it an attractive high growth stock. The company has successfully reported its second and third quarter 2024 financial results, detailing several achievements and activities. As technology partner, Cognizant collaborates with Alnylam to scale IT operations. Alnylam disclosed positive trial outcomes for nucresiran, a treatment for ATTR amyloidosis, and has submitted a regulatory application to the European Medicines Agency for Vutrisiran, indicating progress in their drug development. Notably, the FDA has accepted Alnylam’s supplemental new drug application for Vutrisiran. Several investors seem to have faith in the company’s growth, even though some advisors and asset management groups have reduced stakes. Alnylam has seen strong revenues growth despite some companies selling their shares in the pharmaceutical firm. The company has seen heavy investments from different entities, including $7.01 Million from Parkman Healthcare Partners LLC. Alnylam has announced data suggesting continued therapy efficacy and has expanded a partnership with Medison Pharma. The US Food and Drug Administration is reviewing Alnylam's sNDA for expanded Amvuttra use.
Alnylam Pharmaceuticals News Analytics from Tue, 30 Apr 2024 07:00:00 GMT to Fri, 06 Dec 2024 11:03:20 GMT -
Rating 8
- Innovation 7
- Information 7
- Rumor -6
